- Home
- RADX vs RDI Comparison
RADX vs RDI Comparison
Compare RADX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- RDI
- Stock Information
- Founded
- RADX 2021
- RDI 1937
- Country
- RADX Australia
- RDI United States
- Employees
- RADX N/A
- RDI N/A
- Industry
- RADX
- RDI Movies/Entertainment
- Sector
- RADX
- RDI Consumer Discretionary
- Exchange
- RADX NYSE
- RDI Nasdaq
- Market Cap
- RADX 32.5M
- RDI 30.6M
- IPO Year
- RADX N/A
- RDI N/A
- Fundamental
- Price
- RADX $4.25
- RDI $1.33
- Analyst Decision
- RADX Strong Buy
- RDI Hold
- Analyst Count
- RADX 2
- RDI 1
- Target Price
- RADX $13.50
- RDI $2.40
- AVG Volume (30 Days)
- RADX 22.4K
- RDI 32.9K
- Earning Date
- RADX 02-26-2025
- RDI 08-13-2025
- Dividend Yield
- RADX N/A
- RDI N/A
- EPS Growth
- RADX N/A
- RDI N/A
- EPS
- RADX N/A
- RDI N/A
- Revenue
- RADX $204,609.00
- RDI $205,644,000.00
- Revenue This Year
- RADX N/A
- RDI $7.47
- Revenue Next Year
- RADX N/A
- RDI $13.22
- P/E Ratio
- RADX N/A
- RDI N/A
- Revenue Growth
- RADX N/A
- RDI N/A
- 52 Week Low
- RADX $3.50
- RDI $1.17
- 52 Week High
- RADX $50.82
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- RDI 50.93
- Support Level
- RADX N/A
- RDI $1.24
- Resistance Level
- RADX N/A
- RDI $1.31
- Average True Range (ATR)
- RADX 0.00
- RDI 0.06
- MACD
- RADX 0.00
- RDI -0.00
- Stochastic Oscillator
- RADX 0.00
- RDI 62.50
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.